GRAIL (NASDAQ:GRAL) CFO Sells $671,579.00 in Stock

GRAIL, Inc. (NASDAQ:GRAL) CFO Aaron Freidin sold 7,900 shares of the stock in a transaction dated Thursday, August 27th. The shares were sold at an average price of $85.01, for a total transaction of $671,579.00. Following the completion of the sale, the chief financial officer owned 253,083 shares of the company’s stock, valued at approximately $21,514,585.83. The trade was a 3.03% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

GRAIL Price Performance

Shares of GRAIL stock opened at $80.56 on Thursday. The stock’s 50 day simple moving average is $71.97 and its 200-day simple moving average is $62.96. The stock has a market cap of $3.60 billion, a P/E ratio of -8.26 and a beta of 3.25. GRAIL, Inc. has a 1-year low of $31.75 and a 1-year high of $118.84.

GRAIL (NASDAQ:GRAL) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($2.56) EPS for the quarter, topping analysts’ consensus estimates of ($2.66) by $0.10. GRAIL had a negative return on equity of 15.88% and a negative net margin of 236.95%.The firm had revenue of $44.69 million for the quarter, compared to the consensus estimate of $42.39 million. As a group, research analysts expect that GRAIL, Inc. will post -10.41 EPS for the current fiscal year.

Analysts Set New Price Targets

Several analysts have recently commented on the stock. Piper Sandler lifted their price target on shares of GRAIL from $54.00 to $56.00 and gave the company a “neutral” rating in a research report on Wednesday, May 6th. Wall Street Zen upgraded GRAIL from a “sell” rating to a “hold” rating in a research report on Saturday, May 9th. Mizuho upped their price target on GRAIL from $58.00 to $65.00 and gave the company a “neutral” rating in a research note on Wednesday, July 15th. TD Cowen reiterated a “buy” rating on shares of GRAIL in a report on Wednesday, July 15th. Finally, Wolfe Research initiated coverage on GRAIL in a research report on Tuesday, June 2nd. They set a “peer perform” rating for the company. Four equities research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, GRAIL presently has a consensus rating of “Hold” and an average target price of $67.78.

Institutional Trading of GRAIL

Hedge funds have recently made changes to their positions in the business. Bank of America Corp DE grew its stake in GRAIL by 29.0% during the 1st quarter. Bank of America Corp DE now owns 914,114 shares of the company’s stock worth $47,241,000 after purchasing an additional 205,611 shares in the last quarter. Russell Investments Group Ltd. boosted its holdings in GRAIL by 255.6% in the second quarter. Russell Investments Group Ltd. now owns 28,403 shares of the company’s stock valued at $1,939,000 after purchasing an additional 20,416 shares in the last quarter. Northwestern Mutual Wealth Management Co. boosted its holdings in shares of GRAIL by 154,361.0% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 91,132 shares of the company’s stock valued at $7,531,000 after buying an additional 91,073 shares in the last quarter. Vanguard Group Inc. grew its holdings in shares of GRAIL by 9.0% during the fourth quarter. Vanguard Group Inc. now owns 1,980,783 shares of the company’s stock worth $169,535,000 after purchasing an additional 163,790 shares during the last quarter. Finally, WIM INVESTMENT MANAGEMENT Ltd grew its stake in GRAIL by 68.9% during the 4th quarter. WIM INVESTMENT MANAGEMENT Ltd now owns 106,400 shares of the company’s stock worth $9,107,000 after buying an additional 43,400 shares during the last quarter.

About GRAIL

GRAIL, Inc (NASDAQ: GRAL) is a biotechnology company dedicated to the early detection of cancer through a multi-cancer blood test. Leveraging advances in next-generation sequencing, cell-free DNA (cfDNA) analysis and machine learning, GRAIL has developed the Galleri™ test, which aims to identify more than 50 types of cancer at their earliest stages. The company’s platform analyzes methylation patterns in circulating tumor DNA to pinpoint tumor presence and tissue of origin, enabling physicians to pursue timely diagnostic follow-up.

Founded in 2016 as a spin-out from Illumina, GRAIL established its headquarters in Menlo Park, California, with additional research and operations centers in the United Kingdom.